Emergent BioSolutions [EBS]: VaxGen [VXGN]: PharmAthene [PIP]: HHS Awards Emergent BioSolutions Potential $187M for New Anthrax Vaccine

September 2010
TR2: Terror Response Technology Report;9/29/2010, Vol. 6 Issue 20, p15
Trade Publication
The article reports on a potential 186.6 million-U.S. dollar contract received by biopharmaceutical firm Emergent BioSolutions from the Biomedical Advanced Research and Development Authority (BARDA) to resume development of a next-generation recombinant protective antigen (rPA) anthrax vaccine product candidate. It cites that the award comes after Emergent bought the assets and rights to an rPA anthrax vaccine product candidate and related technology from VaxGen. It notes that BARDA has separate contracts with PharmAthene and Pfenex for the vaccines.


Related Articles

  • PharmAthene Gets $78.4M More in Anthrax Pact Modification. Hollingsworth, Catherine // BioWorld Today;2/24/2010, Vol. 21 Issue 36, p1 

    The article reveals that PharmAthene could receive additional government funding of up to 78.4 million U.S. dollars for a major contract modification with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop its next generation SparVax anthrax vaccine. PharmAthene...

  • VaxGen Sells Anthrax Vaccine to Emergent for Potential $10M. Hollingsworth, Catherine // BioWorld Today;5/6/2008, Vol. 19 Issue 88, p1 

    The article reports on the decision of VaxGen Inc. to sell the rights to its next-generation anthrax vaccine candidate and related technology to Emergent BioSolutions Inc. The deal is estimated to have a total value of $10 million. Proceeds from the sale will be placed by VaxGen into its cash...

  • PharmAthene, Emergent Land NIAID Anthrax Vaccine Contracts.  // BioWorld Today;9/29/2008, Vol. 19 Issue 189, p2 

    The article reports on the contracts signed by PharmAthene Inc. and Emergent BioSystems involving the development of anthrax vaccines. PharmAthene sign a multiyear contract with the National Institute of Allergy and Infectious Diseases which covers the development of a third-generation...

  • BARDA RFP off: PharmAthene Slammed, Emergent Bruised. Young, Donna // BioWorld Today;12/9/2009, Vol. 20 Issue 236, p1 

    The article describes the effects of the withdrawal of the request for proposal (RFP) by the Biomedical Research and Development Authority (BARDA) to the share price of PharmAthene Inc. and Emergent BioSolutions Inc. on December 8, 2009. As such, shares of PharmAthene closed at 1.55 U.S....

  • EMERGENT BIOSOLUTIONS/BARDA/NIAID SIGNS FOR UP TO $29.7 MIL.  // Biotech Business;Nov2008, Vol. 21 Issue 11, p6 

    The article states that Emergent BioSolutions Incorporated signed a three-year contract worth $29.7 million with Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) and National Institute of Allergy and Infectious Diseases...

  • OTHER NEWS TO NOTE.  // BioWorld Today;3/16/2007, Vol. 18 Issue 52, p2 

    The article offers news briefs on developments in the pharmaceuticals industry as of March 16, 2007. Crucell NV has licensed its PER.C6 cell production technology to the animal health division of Pfizer Inc. Emergent BioSolutions Inc. entered into a licensing agreement with Coley Pharmaceutical...

  • BARDA Awards Emergency BioSolutions Contract.  // BioWorld Today;9/20/2010, Vol. 21 Issue 181, p3 

    The article reports on a 51 million U.S. dollar contract awarded by the Biomedical Advanced Research and Development Authority to Emergent BioSolutions Inc. to develop a new anthrax vaccine using the protective antigen to stimulate a protective immune response that neutralizes the anthrax toxins.

  • Other News To Note.  // BioWorld Today;9/9/2013, Vol. 24 Issue 172, p5 

    The article reports that Pharmathene Inc. presented the results of its Sparvax anthrax vaccine program at the 2013 Bacillus ACT international anthrax conference in Victoria, British Columbia.

  • Emergent BioThrax Multiyear Pact Worth up to $404M.  // BioWorld Today;10/2/2008, Vol. 19 Issue 192, p3 

    The article announces that Emergent BioSolutions Inc. has signed a new multiyear contract to supply the U.S. government with 14.5 million doses of BioThrax anthrax vaccine. According to the article, the contract extends the government's commitment to purchase BioThrax through the third quarter...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics